Thanks, Peter. The company reported a net loss of $1,900,000 or $1.16 per share for the 3 months ended June 30, 2024, compared to a net loss of $4,200,000 or $10.64 per share for the 3 months ended June 30, 2023. Research and development expense for the 3 months ended June 30, 2024 decreased to $1,900,000 compared to $3,100,000 for the 3 months ended June 30, 2023, primarily due to decreased manufacturing expenses related to drug product releases, partially offset by an increase in expense related to our clinical trial for BP1002 in lymphoma due to increased patient enrollment in 2024. General and administrative expense for the 3 months ended June 30, 2024 June 30, 2023 was $1,200,000 As of June 30, 2024, the company had cash of $4,000,000 compared to $1,100,000 as of December 31, 2023. Net cash used in operating activities for the 6 months ended June 30, 2024 was 4,300,000 dollars compared to $6,900,000 for the comparable period in 2023.